Ubrelvy (ubrogepant) / Merck (MSD), AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ubrelvy (ubrogepant) / AbbVie
NCT04179474: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Completed
1b
40
US
Ubrogepant, Erenumab, Galcanezumab
Allergan
Migraine
12/19
12/19
NCT04818515: Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Completed
1b
26
US
Atogepant, Ubrogepant, UBRELVY
AbbVie
Migraine
06/21
06/21
NCT05892757: Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Completed
1
24
US
Atogepant, QULIPTA, Ubrogepant, UBRELVY
AbbVie
Healthy Volunteers
02/24
02/24
NCT06578585: A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Completed
1
43
US
Ubrogepant, Lu AG09222, Placebo
H. Lundbeck A/S
Migraine
07/25
07/25

Download Options